---
title: "Clearside Biomedical, Inc. (CLSDQ.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/CLSDQ.US.md"
symbol: "CLSDQ.US"
name: "Clearside Biomedical, Inc."
industry: "Pharmaceuticals"
---

# Clearside Biomedical, Inc. (CLSDQ.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | US Market |
| Website | [clearsidebio.com](https://clearsidebio.com) |

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:15.000Z

**Overall: D (0.73)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 168 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -56.78% |  |
| Net Profit YoY | 18.45% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -0.06 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2.98M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 3.33M |  |


**Multi Score**: D

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 58.59% | A |
| Profit Margin | -780.90% | E |
| Gross Margin | 100.00% | A |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -56.78% | E |
| Net Profit YoY | 18.45% | B |
| Total Assets YoY | -60.08% | E |
| Net Assets YoY | -55.08% | E |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -12.81% | D |
| OCF YoY | -56.78% | E |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.16 | D |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 563.45% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Clearside Biomedical, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "58.59%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-780.90%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-56.78%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "18.45%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-60.08%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-55.08%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-12.81%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-56.78%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.16",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "563.45%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Eli Lilly (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | Roche (US.RHHBY) | A | B | B | D | C | B |
| 04 | AstraZeneca (US.AZN) | A | B | C | D | C | B |
| 05 | NOVARTIS AG (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.11 | 68/257 | - | - | - |
| PB | -0.06 | 196/257 | - | - | - |
| PS (TTM) | 0.90 | 30/257 | 1.49 | 1.24 | 1.08 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-13T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 1 | 100% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.57 |
| Highest Target | 90.00 |
| Lowest Target | 90.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/CLSDQ.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/CLSDQ.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/CLSDQ.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.